32.80
1.26%
-0.42
After Hours:
32.80
Agios Pharmaceuticals Inc stock is currently priced at $32.80, with a 24-hour trading volume of 696.45K.
It has seen a -1.26% decreased in the last 24 hours and a +19.06% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $33.85 pivot point. If it approaches the $32.58 support level, significant changes may occur.
Previous Close:
$33.22
Open:
$33.47
24h Volume:
696.45K
Market Cap:
$1.86B
Revenue:
$26.82M
Net Income/Loss:
$-352.09M
P/E Ratio:
-8.3038
EPS:
-3.95
Net Cash Flow:
$-314.56M
1W Performance:
+0.92%
1M Performance:
+19.06%
6M Performance:
+41.14%
1Y Performance:
+28.43%
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 Sidney Street, Cambridge, MA
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
Feb-03-23 | Initiated | Piper Sandler | Overweight |
Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Dec-03-21 | Initiated | BofA Securities | Buy |
Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
Jul-01-21 | Initiated | Raymond James | Mkt Perform |
Jun-10-21 | Initiated | H.C. Wainwright | Buy |
Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-04-20 | Initiated | Barclays | Equal Weight |
Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
May-23-19 | Resumed | Goldman | Neutral |
Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
May-23-18 | Initiated | Citigroup | Buy |
Apr-11-18 | Reiterated | Credit Suisse | Outperform |
Feb-15-18 | Reiterated | Needham | Buy |
Feb-15-18 | Reiterated | SunTrust | Buy |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Aug-10-17 | Reiterated | Needham | Buy |
Aug-08-17 | Reiterated | SunTrust | Buy |
Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
Jun-26-17 | Downgrade | Janney | Buy → Neutral |
Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-24-16 | Initiated | Needham | Buy |
Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Zacks Investment Research
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
GlobeNewswire Inc.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
Agios Reports Business Highlights and First Quarter 2024 Financial Results
GlobeNewswire Inc.
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Agios Pharmaceuticals Inc (AGIO) Revenue 2024
AGIO reported a revenue (TTM) of $26.82 million for the quarter ending December 31, 2023, a +88.36% rise year-over-year.
Agios Pharmaceuticals Inc (AGIO) Net Income 2024
AGIO net income (TTM) was -$352.09 million for the quarter ending December 31, 2023, a -51.89% decrease year-over-year.
Agios Pharmaceuticals Inc (AGIO) Cash Flow 2024
AGIO recorded a free cash flow (TTM) of -$314.56 million for the quarter ending December 31, 2023, a -0.06% decrease year-over-year.
Agios Pharmaceuticals Inc (AGIO) Earnings per Share 2024
AGIO earnings per share (TTM) was -$6.34 for the quarter ending December 31, 2023, a -49.53% decline year-over-year.
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
FOUSE JACQUALYN A | Director |
Apr 10 '24 |
Sale |
27.55 |
7,791 |
214,642 |
137,396 |
FOUSE JACQUALYN A | Director |
Apr 08 '24 |
Option Exercise |
0.00 |
15,934 |
0 |
145,187 |
Foster-Cheek Kaye I | Director |
Mar 07 '24 |
Sale |
31.62 |
1,285 |
40,632 |
5,524 |
Foster-Cheek Kaye I | Director |
Mar 06 '24 |
Sale |
31.99 |
4,415 |
141,236 |
6,809 |
Goff Brian | Chief Executive Officer |
Mar 05 '24 |
Sale |
32.57 |
4,156 |
135,361 |
53,780 |
Burns James William | Chief Legal Officer |
Mar 05 '24 |
Sale |
32.57 |
2,642 |
86,050 |
34,518 |
Gheuens Sarah | Chief Medical Officer |
Mar 05 '24 |
Sale |
32.57 |
2,642 |
86,050 |
36,415 |
Washburn Theodore James Jr. | Principal Accounting Officer |
Mar 05 '24 |
Sale |
31.75 |
1,913 |
60,738 |
2,886 |
Washburn Theodore James Jr. | Principal Accounting Officer |
Mar 05 '24 |
Sale |
32.57 |
1,214 |
39,540 |
3,368 |
Jones Cecilia | Chief Financial Officer |
Mar 05 '24 |
Sale |
32.57 |
672 |
21,887 |
14,840 |
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Cap:
|
Volume (24h):